clinical trial · NCT03335371
Evaluation of TTP399 in Patients With Type 1 Diabetes
Diabetes Mellitus, Type 1TTP399TTP399Placebo Oral Tablet
brief summary
The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.
started
Oct 25, 2017
primary completion
Dec 20, 2019
completion
Jan 6, 2020
last updated
Jul 3, 2023
official title
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol